NovoCure Reports Q3 Earnings Beat and Updates FY26 Financial Outlook
NovoCure (NVCR) reported third-quarter financial results that exceeded both top-line and bottom-line analyst expectations. The company posted GAAP earnings per share of -$0.09, outperforming estimates by $0.14, while revenue reached $193.4 million, representing a 15.8% increase year-over-year. In addition to the earnings beat, NovoCure reported an adjusted EBITDA of $15.7 million for the quarter. The company maintains a strong liquidity position with $463.5 million in cash, cash equivalents, and short-term investments as of September 30, 2026, while providing updated guidance for its fiscal year 2026 outlook.
Tickers: $NVCR